Genmab A/S (NASDAQ:GMAB) Upgraded at Wall Street Zen

Genmab A/S (NASDAQ:GMAB - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

A number of other brokerages also recently weighed in on GMAB. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, Truist Financial increased their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $37.80.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $21.40 on Friday. The company has a market capitalization of $13.73 billion, a price-to-earnings ratio of 12.16, a price-to-earnings-growth ratio of 6.65 and a beta of 0.94. Genmab A/S has a one year low of $17.24 and a one year high of $28.56. The stock has a 50-day simple moving average of $21.04 and a 200 day simple moving average of $20.75.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.23 by $0.08. The company had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. On average, equities research analysts forecast that Genmab A/S will post 1.45 EPS for the current fiscal year.

Institutional Trading of Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. Bank of New York Mellon Corp boosted its stake in Genmab A/S by 4.0% during the fourth quarter. Bank of New York Mellon Corp now owns 71,623 shares of the company's stock valued at $1,495,000 after buying an additional 2,749 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Genmab A/S by 134.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 61,177 shares of the company's stock valued at $1,277,000 after buying an additional 35,073 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Genmab A/S during the fourth quarter valued at about $2,463,000. Sequoia Financial Advisors LLC increased its position in shares of Genmab A/S by 27.8% in the fourth quarter. Sequoia Financial Advisors LLC now owns 22,204 shares of the company's stock worth $463,000 after acquiring an additional 4,835 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the period. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.